<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00826904</url>
  </required_header>
  <id_info>
    <org_study_id>07-0535</org_study_id>
    <secondary_id>R56DK078645</secondary_id>
    <nct_id>NCT00826904</nct_id>
  </id_info>
  <brief_title>Regulation Of Maternal Fuel Supply And Neonatal Adiposity</brief_title>
  <official_title>Regulation Of Maternal Fuel Supply And Neonatal Adiposity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether unrecognized maternal hyperglycemia and&#xD;
      postprandial lipemia early or late in gestation predicts excess neonatal adiposity.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Mounting epidemiologic evidence suggests that maternal obesity and Gestational Diabetes&#xD;
      Mellitus (GDM) independently influence size at birth and disease susceptibility later in&#xD;
      life. A major gap in the understanding of fetal programming is the knowledge of whether and&#xD;
      how exposure to excess maternal fuels in the absence of frank hyperglycemia impacts fetal fat&#xD;
      accretion. The investigators hypothesis is that neonatal adiposity results from unrecognized&#xD;
      maternal hyperglycemia and excess lipid availability in gestation, in part caused by&#xD;
      excessive lipolysis in the white adipose tissue of obese women, some of whom will be&#xD;
      subsequently diagnosed as having GDM. In Aim 1 the investigators will test the hypothesis&#xD;
      that in obese women, some of whom will later be diagnosed with GDM, increased lipolysis and&#xD;
      unrecognized hyperglycemia and hypertriglyceridemia occur earlier in gestation than in lean&#xD;
      women, resulting in increased plasma non-esterified fatty acids (NEFA), glycerol,&#xD;
      triglycerides (TGs), and glucose available for fetal metabolism. In Aim 2 the investigators&#xD;
      will test the hypothesis that fetal adiposity by ultrasound and neonatal adiposity by&#xD;
      Dual-energy X-ray Absorptiometry (DXA) are strongly correlated with excess lipid and glucose&#xD;
      availability in obese mothers early in gestation, regardless of GDM status, and that fasting&#xD;
      biomarkers of neonatal insulin sensitivity will correlate with neonatal adiposity. In Aim 3&#xD;
      the investigators will test the hypothesis that the in-vitro suppression of lipolysis in&#xD;
      white adipose tissue correlates with excess NEFA and TG availability in-vivo and is&#xD;
      predictive of neonatal adiposity. The elucidation of specific derangements in both glucose&#xD;
      and lipid metabolism and their timing in gestation in mothers who deliver infants with excess&#xD;
      adiposity could challenge our current screening methods and entirely redirect our treatment&#xD;
      to target the responsible maternal fuels. On a public health level, this research is&#xD;
      instrumental to the investigators understanding of how an intrauterine environment may&#xD;
      deliver excess glucose and/or lipids to the fetus and contribute to the genesis of the&#xD;
      pediatric obesity epidemic. Such information may result in new treatment strategies in&#xD;
      pregnant women to normalize fetal growth.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">March 20, 2017</completion_date>
  <primary_completion_date type="Actual">March 20, 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in neonatal adiposity by maternal Triglycerides, Glucose</measure>
    <time_frame>14-16, 26-28 weeks gestation</time_frame>
    <description>Prediction of neonatal adiposity by maternal Triglycerides and Glucose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in maternal postprandial lipemia</measure>
    <time_frame>26-28 weeks gestation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in maternal postprandial lipemia</measure>
    <time_frame>14-16, 26-28 weeks gestation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in maternal postprandial glycemia</measure>
    <time_frame>14-16, 26-28 weeks gestation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prediction of neonatal adiposity by placental and maternal adipose tissue lipoprotein lipase (LPL) activity</measure>
    <time_frame>26-28 weeks gestation</time_frame>
    <description>adipose tissue biopsy/Neonatal adiposity by Dual x-ray Absorptiometry (DXA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of neonatal adiposity and fetal growth</measure>
    <time_frame>28-30 weeks gestation</time_frame>
    <description>Neonatal adiposity by Dual-energy X-ray Absorptiometry (DXA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of neonatal adiposity and fetal growth</measure>
    <time_frame>36-37 weeks gestation</time_frame>
    <description>Neonatal adiposity by Dual-energy X-ray Absorptiometry (DXA)</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">59</enrollment>
  <condition>Fetal Macrosomia</condition>
  <condition>Gestational Diabetes</condition>
  <arm_group>
    <arm_group_label>Lean</arm_group_label>
    <description>Healthy, pregnant women with BMI of 20 - 26 kg/m2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Obese</arm_group_label>
    <description>Healthy, obese pregnant women with BMI 30 - 38 kg/m2</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Lean (BMI 20-26 kg/m2)and Obese (BMI 30-38 kg/m2) pregnant women (age 18-35 yr) without&#xD;
        chronic medical conditions or obstetric complications will be enrolled at 12-14 weeks&#xD;
        gestation.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18 - 35 yr&#xD;
&#xD;
          -  Pregnant (12-14 weeks gestation)&#xD;
&#xD;
          -  Lean (BMI 20-26 kg/m2)&#xD;
&#xD;
          -  Obese (BMI 30-38 kg/m2)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt; 18 or &gt; 35 yr&#xD;
&#xD;
          -  Pre-existing diabetes&#xD;
&#xD;
          -  Chronic medical conditions:&#xD;
&#xD;
               1. hypertension,&#xD;
&#xD;
               2. hepatitis,&#xD;
&#xD;
               3. Human immunodeficiency Virus (HIV),&#xD;
&#xD;
               4. Thrombophilias,&#xD;
&#xD;
               5. History of:&#xD;
&#xD;
                    1. thromboembolism,&#xD;
&#xD;
                    2. renal disease,&#xD;
&#xD;
                    3. neurologic diseases,&#xD;
&#xD;
                    4. rheumatologic disorders,&#xD;
&#xD;
                    5. gastrointestinal disease,&#xD;
&#xD;
                    6. cardiac dysfunction, or&#xD;
&#xD;
                    7. pulmonary disease&#xD;
&#xD;
          -  Obstetric conditions:&#xD;
&#xD;
               1. history of stillbirth,&#xD;
&#xD;
               2. severe growth restriction,&#xD;
&#xD;
               3. severe preeclampsia, or&#xD;
&#xD;
               4. placental abruption&#xD;
&#xD;
          -  Medications known to affect lipid or glucose metabolism:&#xD;
&#xD;
               1. Metformin,&#xD;
&#xD;
               2. glucocorticoids,&#xD;
&#xD;
               3. beta agonists or blockers, or&#xD;
&#xD;
               4. antihypertensives&#xD;
&#xD;
          -  Use of recreational drugs, alcohol or tobacco.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Linda A Barbour, MD, MSPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado, Denver</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Colorado Denver</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>January 21, 2009</study_first_submitted>
  <study_first_submitted_qc>January 21, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 22, 2009</study_first_posted>
  <last_update_submitted>October 31, 2019</last_update_submitted>
  <last_update_submitted_qc>October 31, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Fetal programming</keyword>
  <keyword>Fetal macrosomia</keyword>
  <keyword>Fetal health</keyword>
  <keyword>Gestational diabetes</keyword>
  <keyword>Maternal health</keyword>
  <keyword>Maternal obesity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes, Gestational</mesh_term>
    <mesh_term>Fetal Macrosomia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

